Composition:
Application:
Utilisé dans le traitement:
Examiné médicalement par Fedorchenko Olga Valeryevna, Pharmacie Dernière mise à jour le 26.06.2023
Attention! Information sur la page est réservée aux professionnels de la santé! Les informations sont collectées dans des sources ouvertes et peuvent contenir des erreurs significatives! Soyez prudent et revérifiez toutes les informations de cette page!
Top 20 des médicaments avec les mêmes ingrédients:
Diotroxin increases the effect of indirect anticoagulants (perhaps a decrease in their dose).
The use of tricyclic antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid hormones can increase the need for insulin and oral hypoglycemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the dosage mode changes.
Diotroxin reduces the effect of cardiac glycosides.
With the simultaneous use of colestiramine, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrate, furosemide in large doses (250 mg), the content of thyroid hormones not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxine-binding globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zones.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of levothyroxine and require an increase in the dose of Diotroxine.
Diotroxin increases the effect of indirect anticoagulants (perhaps a decrease in their dose).
The use of tricyclic antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid hormones can increase the need for insulin and oral hypoglycemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the dosage mode changes.
Diotroxin reduces the effect of cardiac glycosides.
With the simultaneous use of colestiramine, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrate, furosemide in large doses (250 mg), the content of thyroid hormones not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxine-binding globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zones.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of levothyroxine and require an increase in the dose of Diotroxine.
Diotroxin increases the effect of indirect anticoagulants (perhaps a decrease in their dose).
The use of tricyclic antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid hormones can increase the need for insulin and oral hypoglycemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the dosage mode changes.
Diotroxin reduces the effect of cardiac glycosides.
With the simultaneous use of colestiramine, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrate, furosemide in large doses (250 mg), the content of thyroid hormones not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxine-binding globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zones.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of levothyroxine and require an increase in the dose of Diotroxine.
Diotroxin increases the effect of indirect anticoagulants (perhaps a decrease in their dose).
The use of tricyclic antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid hormones can increase the need for insulin and oral hypoglycemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the dosage mode changes.
Diotroxin reduces the effect of cardiac glycosides.
With the simultaneous use of colestiramine, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrate, furosemide in large doses (250 mg), the content of thyroid hormones not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxine-binding globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zones.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of levothyroxine and require an increase in the dose of Diotroxine.
Diotroxin increases the effect of indirect anticoagulants (perhaps a decrease in their dose).
The use of tricyclic antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid hormones can increase the need for insulin and oral hypoglycemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the dosage mode changes.
Diotroxin reduces the effect of cardiac glycosides.
With the simultaneous use of colestiramine, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrate, furosemide in large doses (250 mg), the content of thyroid hormones not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxine-binding globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zones.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of levothyroxine and require an increase in the dose of Diotroxine.
Diotroxin increases the effect of indirect anticoagulants (perhaps a decrease in their dose).
The use of tricyclic antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid hormones can increase the need for insulin and oral hypoglycemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the dosage mode changes.
Diotroxin reduces the effect of cardiac glycosides.
With the simultaneous use of colestiramine, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrate, furosemide in large doses (250 mg), the content of thyroid hormones not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxine-binding globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zones.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of levothyroxine and require an increase in the dose of Diotroxine.
Diotroxin increases the effect of indirect anticoagulants (perhaps a decrease in their dose).
The use of tricyclic antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid hormones can increase the need for insulin and oral hypoglycemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the dosage mode changes.
Diotroxin reduces the effect of cardiac glycosides.
With the simultaneous use of colestiramine, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrate, furosemide in large doses (250 mg), the content of thyroid hormones not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxine-binding globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zones.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of levothyroxine and require an increase in the dose of Diotroxine.
Diotroxin increases the effect of indirect anticoagulants (perhaps a decrease in their dose).
The use of tricyclic antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid hormones can increase the need for insulin and oral hypoglycemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the dosage mode changes.
Diotroxin reduces the effect of cardiac glycosides.
With the simultaneous use of colestiramine, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrate, furosemide in large doses (250 mg), the content of thyroid hormones not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxine-binding globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zones.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of levothyroxine and require an increase in the dose of Diotroxine.
Diotroxin increases the effect of indirect anticoagulants (perhaps a decrease in their dose).
The use of tricyclic antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid hormones can increase the need for insulin and oral hypoglycemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the dosage mode changes.
Diotroxin reduces the effect of cardiac glycosides.
With the simultaneous use of colestiramine, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrate, furosemide in large doses (250 mg), the content of thyroid hormones not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxine-binding globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zones.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of levothyroxine and require an increase in the dose of Diotroxine.
Diotroxin increases the effect of indirect anticoagulants (perhaps a decrease in their dose).
The use of tricyclic antidepressants with Diotroxin can lead to an increase in the action of antidepressants.
Thyroid hormones can increase the need for insulin and oral hypoglycemic drugs. More frequent control of blood sugar is recommended during the periods of starting treatment with the drug, as well as when the dosage mode changes.
Diotroxin reduces the effect of cardiac glycosides.
With the simultaneous use of colestiramine, colestipol and aluminum hydroxide, the plasma concentration of the drug is reduced by inhibiting its absorption in the intestine.
With simultaneous use with anabolic steroids, asparaginase, tamoxifen, pharmacokinetic interaction at the level of protein binding is possible.
With simultaneous use with phenytoin, salicylates, clofibrate, furosemide in large doses (250 mg), the content of thyroid hormones not bound to plasma proteins increases.
Taking estrogen-containing drugs increases the content of thyroxine-binding globulin, which may increase the need for Diotroxin in some patients. Somatotropin, when used simultaneously with Diotroxin, can accelerate the closure of epiphyseal growth zones.
Taking phenobarbital, carbamazepine and rifampicin may increase the clearance of levothyroxine and require an increase in the dose of Diotroxine.
